Patents by Inventor Peter Peizhi Luo
Peter Peizhi Luo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240417463Abstract: Provided herein are antibodies, masked antibodies (e.g., activatable antibodies), and antigen-binding fragments that target human CD47, polynucleotides encoding the same, therapeutic compositions thereof, and their use to treat CD47-positive diseases such as cancer. The masked antibodies described herein may comprise an IgG1 Fc region.Type: ApplicationFiled: October 27, 2022Publication date: December 19, 2024Applicant: Adagene PTE. LTD.Inventors: Fangyong DU, Peter Peizhi LUO, Yan LI, Bin CAI, Jianfeng SHI, Jiangchun XU, Aaron NGUYEN, Songmao ZHENG, Guizhong LIU, Zhengxi DAI
-
Publication number: 20240279350Abstract: Provided herein are anti-cluster of differentiation 40 (CD40) monoclonal antibodies, as well as conditionally-active variants thereof; and therapeutic and diagnostic methods of using said anti-CD40 monoclonal antibodies.Type: ApplicationFiled: February 16, 2024Publication date: August 22, 2024Inventors: Margot Cucchetti, Fangyong Du, Yan Li, Guizhong Liu, Peter Peizhi Luo, Sunghae Park, Yu Qiu, Ingrid Sassoon
-
Publication number: 20240262923Abstract: Anti-4-1BB and anti-PD-1 binding proteins, as well as bispecific anti-4-1BB/anti-PD-1 binding proteins, including conditionally-active derivatives thereof, are provided. Therapeutic and diagnostic methods of using binding proteins are provided.Type: ApplicationFiled: December 20, 2023Publication date: August 8, 2024Inventors: Marta AMARAL, Christian BEIL, Laurence BERTHOU-SOULIÉ, Joerg BIRKENFELD, Béatrice CAMERON, Margot CUCCHETTI, Tarik DABDOUBI, Klervi DESRUMEAUX, Fangyong DU, Norbert FURTMANN, Soraya HOELPER, Yan LI, Guizhong LIU, Peter Peizhi LUO, Ercole RAO, Ingrid SASSOON, Marion SCHNEIDER, Fabienne SOUBRIER, Emmanuelle VIGNE
-
Publication number: 20240240358Abstract: Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody heavy chain with specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.Type: ApplicationFiled: January 11, 2023Publication date: July 18, 2024Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Yan LI, Fangyong DU
-
Publication number: 20240209091Abstract: Through the hybridoma technique, we got two hybridoma cells secreting anti-CTLA-4 mAb with high affinity, which were named 22G11 and 16C11 respectively. To construct the chimeric antibody light chain and heavy chain expression vectors, the cloned anti-CTL4 antibody's light chain (VL) and heavy chain variable region cDNAs (VH) were respectively fused to the human antibody light and heavy chain constant region genes (CH). Then appropriate light and heavy chain expression vectors were co-transfected into CHO-K1 cells and the clones producing the highest amount of chimeric antibodies were selected. In the end, the purity of the two chimeric antibodies was more than ninety percent. Both of them can bind Jurkat cells specifically as did the commercial anti-CTLA-4 mAb. Western blotting analysis showed that mAbs 22G11 and 16C11 reacted with one specific band with a molecular weight of about 22 kD, further indicating that 22G11 and 16C11 specifically recognized CTLA-4 molecule.Type: ApplicationFiled: March 28, 2022Publication date: June 27, 2024Applicant: ADAGENE PTE. LTDInventors: Peter Peizhi LUO, Guizhong LIU, Hua Chang GONG, Songmao ZHENG
-
Publication number: 20240209092Abstract: Provided herein are compositions and methods for treating cancers using anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibodies, such as activatable anti-CTLA4 antibodies. In some embodiments, combination therapies including an anti-CT-LA4 antibody and an immune checkpoint inhibitor, an anti-CD137 antibody, a vascular endothelial growth factor (VEGF) inhibitor, a chemotherapeutic agent, or a poly ADP ribose polymerase (PARP) inhibitor are provided.Type: ApplicationFiled: April 11, 2022Publication date: June 27, 2024Applicant: ADAGENE INC.Inventors: Peter Peizhi LUO, Guizhong LIU
-
Publication number: 20240150749Abstract: Provided herein are libraries containing synthetic polynucleotides that encode activatable binding polypeptides. Further provided herein are activatable binding polypeptides and polypeptide libraries containing such activatable binding polypeptides. Also provided herein are vectors, vector libraries, cells, kits, and methods of making and using activatable polypeptide libraries.Type: ApplicationFiled: January 11, 2023Publication date: May 9, 2024Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Fangyong Du
-
Publication number: 20240141046Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).Type: ApplicationFiled: May 18, 2023Publication date: May 2, 2024Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Fangyong DU, Zhongzong PAN, Guizhong LIU
-
Patent number: 11952681Abstract: Provided herein are libraries containing synthetic polynucleotides that encode activatable binding polypeptides. Further provided herein are activatable binding polypeptides and polypeptide libraries containing such activatable binding polypeptides. Also provided herein are vectors, vector libraries, cells, kits, and methods of making and using activatable polypeptide libraries.Type: GrantFiled: February 2, 2019Date of Patent: April 9, 2024Assignee: Adagene Inc.Inventors: Peter Peizhi Luo, Fangyong Du
-
Patent number: 11859003Abstract: Provided are antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.Type: GrantFiled: August 21, 2018Date of Patent: January 2, 2024Assignee: Adagene Inc.Inventors: Peter Peizhi Luo, Fangyong Du, Guizhong Liu, Yan Li, Jun Chen, Xiaohong She, Peter Cheung
-
Publication number: 20230287597Abstract: Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody light chain with specific hypervariable regions HVR-L1, HVR-L2, and HVR-L3. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody light chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.Type: ApplicationFiled: January 11, 2023Publication date: September 14, 2023Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Yan LI, Fangyong DU
-
Publication number: 20230242663Abstract: The present application provides compositions and methods for treating cancers in a subject using an anti-CD137 antibody and an agent that induces expression of CD137 on an immune cell and/or induces expression of CD137L on a cancer cell of the subject. In some embodiments, the agent is a cytokine such as IL-2. In some embodiments, the agent is a histone deacetylase (HDAC) inhibitor. In some embodiments, the agent is a DNA-damaging agent.Type: ApplicationFiled: June 23, 2021Publication date: August 3, 2023Applicant: Adagene PTE. LTD.Inventors: Peter Peizhi LUO, Guizhong LIU, Aaron NGUYEN
-
Patent number: 11692036Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).Type: GrantFiled: February 2, 2019Date of Patent: July 4, 2023Assignee: Adagene Inc.Inventors: Peter Peizhi Luo, Fangyong Du, Zhongzong Pan, Guizhong Liu
-
Publication number: 20230203170Abstract: The disclosure relates to antibodies against human CSF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: December 23, 2020Publication date: June 29, 2023Inventors: Fangyong Du, Peter Peizhi Luo, Yan Li, Guizhong Liu, Xiaohong She, Zhengxi Dai
-
Publication number: 20230133118Abstract: The present application provides compositions and methods for treating cancers, including follicular lymphoma, T cell lymphoma and adenoid cystic carcinoma, using an anti-CD137 antibody that specifically binds to an extracellular domain of human CD137. In some embodiment, combination therapies including the anti-CD137 antibody and an immune checkpoint inhibitor, and/or a chemotherapeutic agent are provided. Biomarkers such as total CD137, membrane bound CD137 (mCD137), soluble CD137 (sCD137), CD137 ligand, Ki67, CD8+ effector memory T (Tem) cells, regulatory T (Treg) cells, and natural killer (NK) cell levels for the methods of treatment described herein are also provided.Type: ApplicationFiled: May 13, 2021Publication date: May 4, 2023Applicant: Adagene AGInventors: Peter Peizhi LUO, Guizhong LIU, Changhua GONG
-
Publication number: 20230124669Abstract: Provided are heterodimeric proteins comprising polypeptides having CH3 domains with engineered residues that form disulfide bonds and/or salt bridges. Also provided are activatable antibodies targeting CD3 and/or HER2. Compositions, methods of manufacture and methods of treatment using the heterodimeric proteins and the activatable antibodies are further provided.Type: ApplicationFiled: January 22, 2021Publication date: April 20, 2023Applicants: Adagene AGInventors: Peter Peizhi LUO, Fangyong DU, Guizhong LIU, Zhengxi DAI, Jianfeng SHI, Zhixiong LIN, Yan LI
-
Patent number: 11585014Abstract: Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody light chain with specific hypervariable regions HVR-L1, HVR-L2, and HVR-L3. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody light chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.Type: GrantFiled: August 21, 2017Date of Patent: February 21, 2023Assignee: Adagene Inc.Inventors: Peter Peizhi Luo, Yan Li, Fangyong Du
-
Patent number: 11578426Abstract: Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody heavy chain with specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.Type: GrantFiled: August 21, 2017Date of Patent: February 14, 2023Assignee: Adagene Inc.Inventors: Peter Peizhi Luo, Yan Li, Fangyong Du
-
Patent number: 11485977Abstract: Methods and systems for autoinduction of gene expression, without the need to add exogenous inducers. A dual genetic element system, which includes a first, high copy number genetic element comprising a first gene of interest that is under the control of an inducible promoter, and a second, low copy number genetic element comprising a gene encoding a transcriptional factor which, upon expression, regulates transcription from the inducible promoter, wherein activation of transcription from the inducible promoter does not require addition of an exogenous inducer.Type: GrantFiled: December 19, 2014Date of Patent: November 1, 2022Assignee: ADAGENE, INC.Inventors: Fangyong Du, Peter Peizhi Luo
-
Publication number: 20220204637Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.Type: ApplicationFiled: December 28, 2021Publication date: June 30, 2022Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Fangyong DU, Yan LI, Guizhong LIU, Jun CHEN, Xiaohong SHE, Peter CHEUNG